|
|
|
|
||
interesting move by abbve news follows Reata's decision last Thursday to reacquire the global rights to several drugs from AbbVie. Under the terms of the deal, Reata agreed to pay AbbVie $330 million comprised of $75 million up front with the balance paid in 2020 and 2021. Voyager and nbix are going after same market for Friedreich's ataxia. Could this be reason why abbv gave rights back and may use money to help buy someone???? |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
46544 | Re: interesting move by abbv | ashtonb22 | 0 | 10/14/2019 11:46:03 PM |